An Automated Tool for Finding Cancer-Fighting Peptide Targets
ProTECT is an automated pipeline that identifies cancer-specific peptide neoepitopes from patient sequencing data, processing samples in under 30 minutes.
Quick Facts
What This Study Found
ProTECT automates cancer neoepitope peptide identification from patient data, identifying recurrent neoepitopes from TMPRSS2-ERG fusions and SPOP mutations in prostate cancer.
Key Numbers
326 samples; <30 min per sample; identified TMPRSS2-ERG and SPOP neoepitopes; free/open-source
How They Did This
Computational pipeline development with validation on 326 TCGA prostate adenocarcinoma samples. Includes alignment, HLA haplotyping, mutation calling, peptide:MHC prediction, and ranking.
Why This Research Matters
Personalized cancer vaccines depend on identifying the right peptide targets. ProTECT makes this reproducible and scalable, potentially accelerating clinical adoption.
The Bigger Picture
As cancer immunotherapy becomes more personalized, tools that rapidly identify patient-specific peptide targets will be essential infrastructure for clinical implementation.
What This Study Doesn't Tell Us
Computational predictions require experimental validation. Predicted neoepitopes may not be immunogenic in vivo.
Questions This Raises
- ?How does ProTECT's prediction accuracy compare to experimentally validated neoepitopes?
- ?Can ProTECT be integrated into clinical workflows?
- ?How well do predicted neoepitopes translate to actual T cell responses?
Trust & Context
- Key Stat:
- <30 min Per sample processing time for identifying cancer neoepitope peptides from raw sequencing data
- Evidence Grade:
- Computational tool validated on a large dataset. Strong technical demonstration but predicted peptides require wet-lab confirmation.
- Study Age:
- Published in 2020. The neoepitope prediction field has continued to advance.
- Original Title:
- ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.
- Published In:
- Frontiers in immunology, 11, 483296 (2020)
- Authors:
- Rao, Arjun A, Madejska, Ada A, Pfeil, Jacob, Paten, Benedict, Salama, Sofie R, Haussler, David
- Database ID:
- RPEP-05089
Evidence Hierarchy
Frequently Asked Questions
What are cancer neoepitopes?
Neoepitopes are small peptide fragments created by mutations unique to a patient's tumor. Because they're not found in normal cells, the immune system can be trained to recognize and attack cells displaying these peptides.
Why is automating neoepitope prediction important?
Identifying the right peptide targets from tumor data previously required multiple separate tools and significant expertise. ProTECT streamlines this into a single automated pipeline, making personalized cancer immunotherapy more accessible.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05089APA
Rao, Arjun A; Madejska, Ada A; Pfeil, Jacob; Paten, Benedict; Salama, Sofie R; Haussler, David. (2020). ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.. Frontiers in immunology, 11, 483296. https://doi.org/10.3389/fimmu.2020.483296
MLA
Rao, Arjun A, et al. "ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy.." Frontiers in immunology, 2020. https://doi.org/10.3389/fimmu.2020.483296
RethinkPeptides
RethinkPeptides Research Database. "ProTECT-Prediction of T-Cell Epitopes for Cancer Therapy." RPEP-05089. Retrieved from https://rethinkpeptides.com/research/rao-2020-protectprediction-of-tcell-epitopes
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.